

BIORELIANCE CORP  
Form SC TO-C  
December 24, 2003

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

SCHEDULE TO

(Rule 14d-100)

Tender Offer Statement Under Section 14(d)(1) or Section 13(e)(1)  
of the Securities Exchange Act of 1934

---

BIORELIANCE CORPORATION

(Name of Subject Company (Issuer))

BASEBALL ACQUISITION CORPORATION (Offeror)  
INVITROGEN CORPORATION (Offeror Parent)

(Names of Filing Persons (Identifying status as offeror, issuer or other person))

---

COMMON STOCK, PAR VALUE \$0.01 PER SHARE  
(Title of Class of Securities)

---

090951104

(CUSIP Number of Class of Securities)

---

Gregory T. Lucier  
President and Chief Executive Officer  
INVITROGEN CORPORATION  
1600 Faraday Avenue  
Carlsbad, CA 92008  
Telephone: (760) 603-7200

(Name, address and telephone number of person authorized to receive  
notices and communications on behalf of filing persons)

---

Edgar Filing: BIORELIANCE CORP - Form SC TO-C

Copy to:

Mara H. Rogers, Esq.  
Fulbright & Jaworski L.L.P.  
666 Fifth Avenue  
New York, New York 10103  
Telephone: (212) 318-3000

**Calculation of Filing Fee**

<u>Transaction Value</u>	<u>Amount of Filing Fee</u>
Not applicable	Not applicable

Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing

Amount Previously Paid:	Not Applicable	Filing Party:	Not Applicable
Form or Registration No.:	Not Applicable	Date Filed:	Not Applicable

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes to designate any transactions to which this statement relates:

third-party tender offer subject to Rule 14d-1.

issuer tender offer subject to Rule 13e-4.

going-private transaction subject to Rule 13e-3.

amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer:

---



---



---

**TABLE OF CONTENTS**

**Item 12: EXHIBITS**

**EXHIBIT INDEX**

**EX-(A)(5)(1)-JOINT PRESS RELEASE**

**EX-(A)(5)(2)-PRESENTATION MATERIALS FROM WEBCAST**

**Item 12: EXHIBITS**

- (a)(5)(1) Joint press release issued by Invitrogen Corporation and BioReliance, Inc. on December 24, 2003
- (a)(5)(2) Presentation materials from webcast hosted by Invitrogen Corporation and BioReliance Corporation on December 24, 2003

**EXHIBIT INDEX**

- (a)(5)(1) Joint press release issued by Invitrogen Corporation and BioReliance, Inc. on December 24, 2003
- (a)(5)(2) Presentation materials from webcast hosted by Invitrogen Corporation and BioReliance Corporation on December 24, 2003